

Effective **May 1, 2024**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

Addition of ustekinumab biosimilars – all adult patients on Stelara must switch by November 1, 2024

1. Update to Alberta Drug Benefit List (ADBL)

On May 1, 2024, two new ustekinumab biosimilar drugs, Jamteki and Wezlana, were listed on the Alberta Drug Benefit List (ADBL) for the treatment of plaque psoriasis and will be subject to the Alberta Biosimilar Initiative.

2. Coverage

Effective May 1, 2024, all new ustekinumab starts for plaque psoriasis are covered with a biosimilar version of ustekinumab. Adult patients currently taking Stelara will be required to switch to a biosimilar version by November 1, 2024 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.